| *Sponsored
Breaking News Puts (Nasdaq: PMCB) On Radar Watch Wednesday (Solid Green Start)
August 20th Dear Reader,
PharmaCyte Biotech, Inc. (Nasdaq: PMCB) is off to a solid start as support could be developing at key chart levels.
As I mentioned previously, PMCB had moved above 2 key chart support levels in its 5-Day Simple Moving Average (SMA) and its 5-Day Exponential Moving Average (EMA).
And as a battle of psychological resistance at the $1.00 level appears to be unfolding this morning, it could be critical to watch these lines/levels closely.
On top of that, PMCB announced this morning the closing of $7Mn in financing.
Don't forget. PMCB is a low float idea with just over 6Mn shares in its float. This means volatility potential could be heightened significantly on a daily basis.
Take a moment to review my initial (Nasdaq: PMCB) report below and consider this profile for your radar. -----
In recent years, an emerging player in the life sciences field has been working quietly on an innovative approach that could reshape how certain serious diseases are treated.
By focusing on novel cell‑based technologies, this organization is exploring therapeutic strategies that address conditions in ways traditional methods have struggled to achieve.
Their work sits at the intersection of biotechnology and unmet medical need, where the potential to improve patient outcomes is vast.
Few companies are advancing this kind of platform, and the forward momentum achieved to date suggests it’s worth taking a closer look at what’s unfolding.
And with a low float and key chart positioning, this under-the-radar Nasdaq biotech has taken over my watchlist:
PharmaCyte Biotech, Inc. (Nasdaq: PMCB)
PharmaCyte is a biotechnology company that is evaluating its signature live-cell encapsulation technology, Cell-in-a-Box®, for potential development of cellular therapies for cancer, diabetes, and malignant ascites, while also exploring the opp. for other strategic acquisitions.
And based on several potential catalysts, (Nasdaq: PMCB) has taken over the top spot on my watchlist. Check them out:
#1. A Low Float Could Create A Volatile Environment (Daily).
#2. A Major $7Mn Capital Raise Helps Strengthen Balance Sheet, Allows Continued Pursuit Of Strategic Alternatives.
#3. Cellulose-Based Encapsulation Could Enable Targeted Chemotherapy With Long-Term Cell Protection.
#4. PMCB Moves Above 2 Key Lines Of Potential Support.
But more on those in a second...
Overview - Key Details About PharmaCyte Biotech, Inc. (Nasdaq: PMCB)
PharmaCyte Biotech, Inc. is a biotechnology company focused on developing cellular therapies for cancer using its proprietary cellulose-based live cell encapsulation technology, known as Cell-in-a-Box®.
This platform technology is intended to support therapies for several types of cancer, including locally advanced, inoperable, non-metastatic pancreatic cancer (LAPC). The current generation of the company’s product candidate is referred to as CypCaps™.
Cell-in-a-Box® Technology
The Cell-in-a-Box® encapsulation technology is designed to present genetically engineered live human cells to targeted tissues. Using this approach, pinhead-sized, cellulose-based, porous capsules are created in which genetically modified live cells can be encapsulated, grown, and cryopreserved until needed.
In laboratory studies, encapsulated cells have been shown to survive and flourish within this protective microenvironment. The cellulose capsules protect the cells from environmental challenges such as shear forces from bioreactors or passage through catheters and needles. The capsules are composed largely of cellulose (cotton) and are bioinert.
Therapeutic Development for Pancreatic Cancer
PharmaCyte has been developing therapies for pancreatic tumors that use live genetically engineered human cells, encapsulated via the Cell-in-a-Box® technology, to convert a cancer prodrug into its active, cancer-killing form. The encapsulated cells are placed as close as possible to a tumor site, where administration of the prodrug enables conversion into an active drug at the targeted location.
The company believes this prodrug/activator approach enhances potency while limiting systemic exposure. It is also intended to create a zone of clearance around blood vessels adjacent to tumors, which may improve prospects for surgical resection of LAPC and enhance survival outcomes.
Future Directions
Alongside reviewing its collaboration with SG Austria, PharmaCyte is exploring alternative approaches to expand the prodrug/activator technology platform. These discussions may extend the technology’s applications toward tightly controlled use of highly toxic cancer-killing drugs within perivascular spaces.
Grab Source And More Here: Form 10-K -----
And as I mentioned above, (Nasdaq: PMCB) has several potential catalysts to consider. Take a look:
#1. PMCB Potential Catalyst - A Low Float Could Create A Volatile Environment (Daily).
According to info from the Yahoo Finance website, PMCB has a fairly low float.
The website reports this profile to have roughly 6.08Mn shares in its float.
Why is that important? It's important on one crucial level. Volatility potential.
If positive company news appears in the midway part of 2025, could it provide a breakout spark? -----
#2. PMCB Potential Catalyst - A Major $7Mn Capital Raise Helps Strengthen Balance Sheet, Allows Continued Pursuit Of Strategic Alternatives.
PharmaCyte Biotech, Inc. Announces $7Mn Capital Raise Led by Existing In-vest-ors
LAS VEGAS, August 18, 2025--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (Nasdaq:PMCB) ("PharmaCyte" or the "Company") announced today that it has entered into a securities purchase agreement for a $7.0Mn financing with existing in-vest-ors involving the sale of 7,000 shares of its newly designated Series C convertible preferred st-ock ("preferred st-ock"), with a stated value of $1k per share, convertible into an aggregate of 7Mn shares of its common st-ock and unregistered common st-ock purchase warrants to purchase up to an aggregate of 7Mn shares of its common st-ock in a private placement. The private placement is expected to close on or about August 19, 2025, subject to the satisfaction of customary closing conditions.
GP Nurmenkari Inc. is acting as the sole placement agent for the private placement.
"This financing, priced at a premium to our current market price and led by our existing in-vest-ors, reflects strong confidence in PharmaCyte’s future," said Josh Silverman, Interim Chief Executive Officer of PharmaCyte. "It meaningfully strengthens our balance sheet, positions us to enhance shareholder value, and enables us to continue pursuing strategic alternatives that we believe can maximize long-term returns for our stockholders."
...
Read the full article here. -----
#3. PMCB Potential Catalyst - Cellulose-Based Encapsulation Could Enable Targeted Chemotherapy With Long-Term Cell Protection.
PharmaCyte Biotech’s Cell-in-a-Box® technology could present itself as a key potential catalyst through its cellulose-based encapsulation material, which offers distinct advantages over competing methods.
Unlike other materials that degrade or trigger immune responses, these capsules remain stable, protecting therapeutic cells without damage or immune attack.
Importantly, the encapsulated cells can be stored long-term, shipped globally, and recovered with high viability.
This durability enables targeted chemotherapy approaches, potentially improving efficacy while reducing side effects.
With growing unmet needs in pancreatic cancer, this platform could position the company for significant clinical and market opp's.
Pancreatic cancer is increasing in most industrialized countries. The American Cancer Society estimated that in 2023 there were 64,000 people in the U.S. diagnosed with pancreatic cancer.
It also estimated 51,000 patients with pancreatic cancer died in 2023. Pancreatic cancer accounts for about 3% of all cancers in the U.S. and about 7% of all cancer deaths.
Learn more here. -----
#4. PMCB Potential Catalyst - PMCB Moves Above 2 Key Lines Of Potential Support.
Take a look at PMCB's chart over the past 2 weeks: | 
No comments:
Post a Comment